sargramostim
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Imreplys | — | 2025-08-21 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | LEUKINE | — | 1995-09-15 – 2018-03-29 | fda.gov ↗ |
| Approved | US (FDA) | LEUKINE | — | 1991-03-05 | fda.gov ↗ |
Trials 297 · started per year
Also used as a comparator or background therapy in 289 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT00091286 Background | Mar 2003 → Feb 2008 | colorectal cancer | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 179 trials | ||||||
| Phase 1 | NCT05544968 Background | Mar 2026 → Jan 2028 expected | Hodgkins lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma +2 | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1 | NCT07374029 Background | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT07377435 Background | Jan 2026 → Mar 2028 expected | plasma cell myeloma, refractory plasma cell neoplasm | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT07027748 Background | Jun 2025 → Jul 2027 expected | neuroblastoma | Steven DuBois, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06514898 Background | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT06799026 Background | Jan 2025 → Sep 2028 expected | plasma cell myeloma | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT06254326 Background | Sep 2024 → Dec 2027 expected | oligodendroglioma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT05421897 Background | Nov 2022 → Jan 2026 overdue | neuroblastoma | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04978727 Background | Jul 2022 → Dec 2027 expected | anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, diffuse intrinsic pontine glioma +3 | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05238558 Background | Jan → Oct 2022 | colorectal cancer | Hubro Therapeutics AS | Completed | No outcome recorded |
| Phase 1 | NCT04963413 Background | Jan 2022 → Sep 2023 | glioblastoma | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT05307835 Background | Dec 2021 → Jun 2026 overdue | esophageal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04861948 Background | May 2021 → Jul 2022 | lung adenocarcinoma, osteosarcoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT03743298 Background | Apr 2021 → May 2024 | metastatic melanoma | Aivita Biomedical, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04810910 Background | Mar 2021 → Mar 2025 | pancreatic exocrine neoplasm | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT07504484 Background | Oct 2020 → Dec 2023 | colorectal cancer, non-small cell lung carcinoma | Ying Yuan, MD | Completed | No outcome recorded |
| Phase 1 | NCT04270149 Background | Sep 2020 → May 2025 overdue | breast cancer | Herbert Lyerly | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04040231 Background | Jul 2019 → Nov 2024 | Wilms tumor, malignant pleural mesothelioma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04144023 Background | Jun 2019 → Dec 2027 expected | ductal breast carcinoma in situ | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT03879694 Background | Jun 2019 → Feb 2025 | atypical carcinoid tumor, lung carcinoid tumor, pancreatic neuroendocrine tumor | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03615404 Background | Oct 2018 → Nov 2019 | brain cancer, glioblastoma, medulloblastoma | Gary Archer Ph.D. | Completed | No outcome recorded |
| Phase 1 | NCT03332667 Background | Sep 2018 → Feb 2024 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT03334305 Background | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT03396575 Background | Jul 2018 → Mar 2025 | diffuse intrinsic pontine glioma | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT03538314 Background | Jul 2018 → Oct 2022 | melanoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1 | NCT03645148 Background | Oct 2017 → Nov 2020 | exocrine pancreatic carcinoma | Zhejiang Provincial People's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02334865 Background | Apr 2017 → Sep 2022 overdue | plasma cell myeloma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02780401 Background | Sep 2016 → Oct 2020 | Her2-receptor negative breast cancer, axillary neoplasm, female breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT02933944 Background | Sep 2016 → Feb 2019 | rectal cancer | Targovax ASA | Terminated | No outcome recorded |
| Phase 1 | NCT02840708 Comparator | May → Dec 2016 | autoimmune pulmonary alveolar proteinosis | Niigata University Medical & Dental Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02444546 Background | Jun 2015 → Jul 2018 | anaplastic oligodendroglioma, atypical teratoid rhabdoid tumor, childhood astrocytic tumor, childhood medulloblastoma +3 | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02470559 Background | Jun 2015 → Feb 2017 | fallopian tube carcinoma, malignant ovarian serous tumor, ovarian carcinoma, ovarian clear cell cancer +1 | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02240537 Background | Jan 2015 → Dec 2016 | acute myeloid leukemia, myelodysplastic syndrome, smoldering plasma cell myeloma | Benovus Bio, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02276300 Background | Dec 2014 → Jul 2017 | breast cancer, gastric cancer | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT02130869 Background | Oct 2014 → Dec 2017 | lymphoma, neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02149225 Background | Oct 2014 → Jun 2018 | glioblastoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02019524 Background | Sep 2013 → Dec 2016 | breast cancer, ovarian cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT01536054 Background | Aug 2012 → Apr 2015 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01403285 Background | Aug 2011 → Apr 2014 | glioblastoma | Immatics Biotechnologies GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT01222221 Background | Jul 2010 → Feb 2015 | central nervous system neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00669734 Background | Feb 2010 → Sep 2021 overdue | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01022255 Background | Jan 2010 → Oct 2013 | follicular lymphoma | Icon Genetics GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01081808 Background | Oct 2009 → Dec 2014 | metastatic malignant neoplasm | Roger Williams Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00972309 Background | May 2009 → Feb 2015 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01673217 Background | Apr 2009 → Oct 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00850785 Background | Jan 2009 → May 2012 | non-small cell lung carcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT00803569 Background | Nov 2008 → Jan 2011 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00569296 Background | Nov 2007 → Dec 2014 | lung cancer | Roger Williams Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00561275 Background | Oct 2007 → May 2008 | esophageal cancer | Japanese Foundation for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00834665 Background | Dec 2006 → Dec 2017 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00398138 Background | Oct 2006 → Jun 2009 | leukemia, lung cancer, malignant mesothelioma, myelodysplastic syndrome +1 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00374049 Background | Jun 2006 → Jan 2008 | prostate cancer | Olivera Finn | Completed | No outcome recorded |
| Phase 1 | NCT00568763 Background | Nov 2005 → May 2010 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00113984 Background | Jun 2005 → Feb 2008 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00450307 Background | Jun 2005 → Apr 2013 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00217373 Background | Jun 2005 → Jan 2013 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00477815 Background | May 2005 → Jul 2011 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00301951 Background | Sep 2004 → Jul 2009 | leukemia, myelodysplastic syndrome, plasma cell neoplasm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00091273 Background | Jun 2004 → Feb 2006 | ovarian cancer, primary peritoneal carcinoma | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00436761 Background | May 2004 → ? | childhood malignant neoplasm | Milton S. Hershey Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00079157 Background | Feb 2004 → Dec 2007 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00064129 Background | May 2003 → Jan 2011 | prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00304018 Background | Oct 2002 → Mar 2009 | leukemia, myelodysplastic syndrome, plasma cell neoplasm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00436254 Background | Oct 2001 → Mar 2010 | HER2 positive breast carcinoma, female breast carcinoma, ovarian carcinoma, ovarian germ cell tumor | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00027807 Background | Oct 2001 → Sep 2010 | breast cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00841399 Background | Jul 2001 → Sep 2012 | breast cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT00012376 Background | Mar 2001 → Jan 2010 | acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32), acute myeloid leukemia, inv(16)(p13.1;q22) +7 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005576 Background | Jan 2001 → Mar 2002 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00016042 Background | Jan 2001 → ? | colorectal cancer, kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00069940 Background | Dec 2000 → Aug 2006 | central nervous system neoplasm, gastrointestinal stromal tumor, sarcoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00014560 Background | Sep 2000 → Feb 2003 | leukemia, lymphoma | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00005787 Background | Sep 1999 → Jan 2002 | lymphoma, neutropenia | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00003959 Background | Jun 1999 → Dec 2001 | leukemia, myelodysplastic syndrome | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003567 Background | May 1999 → Jan 2007 | cancer of unknown primary site, central nervous system neoplasm, lymphoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00005023 Background | Mar 1999 → Jan 2001 | breast cancer, lung cancer, ovarian cancer | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00004162 Background | Jun 1997 → Jan 2001 | lymphoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT00003003 Background | Sep 1996 → Aug 2000 | leukemia | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00003002 Background | Apr 1996 → Jan 2004 | breast cancer, lung cancer, ovarian cancer | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00002787 Background | Mar 1996 → Dec 2002 | plasma cell myeloma | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Completed | No outcome recorded |
| Phase 1/239 trials | ||||||
| Phase 1/2 | NCT07437963 Background | Jul 2026 → Sep 2029 expected | ganglioneuroblastoma, neuroblastoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06173219 Background | Aug 2025 → Jul 2026 overdue | neoplasm | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06934538 Background | Jun 2025 → Jun 2028 expected | colorectal cancer | Brenus Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05269381 Background | Mar 2022 → Mar 2028 expected | breast adenocarcinoma, carcinosarcoma of the corpus uteri, cervical carcinoma, cutaneous melanoma +16 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04929652 Background | Jun 2021 → Jun 2022 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05101356 Background | Jan 2021 → Dec 2030 | adenocarcinoma, metastatic malignant neoplasm | University of California, Davis | Suspended | No outcome recorded |
| Phase 1/2 | NCT03761914 Background | Sep 2019 → Jul 2022 | acute myeloid leukemia, colorectal cancer, ovarian cancer, small cell lung carcinoma +1 | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT02223312 Background | Jul 2017 → Oct 2018 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02705703 Background | Jul 2017 → Oct 2018 | metastatic malignant neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02709993 Background | Jul 2017 → Oct 2020 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03559413 Background | Jun 2016 → Mar 2022 | childhood acute lymphoblastic leukemia | University Children's Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT02620865 Background | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02275416 Background | Feb 2015 → Oct 2016 | melanoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT02173093 Background | Nov 2014 → Dec 2019 | neuroblastoma | University of Virginia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02092116 Background | Mar 2014 → Aug 2015 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01784913 Background | Apr 2013 → Jul 2015 | prostate cancer | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01789099 Background | Apr 2013 → Feb 2016 | non-small cell lung carcinoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01827137 Background | Apr 2013 → Dec 2016 | plasma cell myeloma | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01757626 Background | Dec 2012 → Dec 2026 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02261714 Background | Dec 2012 → May 2019 | pancreatic adenocarcinoma | Targovax ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01704781 Background | Sep 2012 → Aug 2014 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01627678 Background | Sep 2012 → Nov 2013 | HIV infectious disease | Bionor Immuno AS | Completed | No outcome recorded |
| Phase 1/2 | NCT01592045 Background | Aug 2012 → Jun 2014 | neuroblastoma | United Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01653665 Comparator | Aug 2012 → Jan 2015 | critical illness polyneuropathy, immunodeficiency disease, infectious disease with sepsis | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 1/2 | NCT01580696 Background | Apr 2012 → Jul 2016 | endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneum cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1/2 | NCT01081223 Background | Apr 2010 → Mar 2011 | glioblastoma | TVAX Biomedical | Completed | No outcome recorded |
| Phase 1/2 | NCT00791037 Background | Oct 2008 → Jul 2013 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00204516 Background | Apr 2007 → Aug 2011 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT00302861 Background | Mar 2006 → ? | B-cell chronic lymphocytic leukemia | Genitope Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00546377 Background | Jul 2005 → May 2014 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00939510 Background | Jul 2005 → Oct 2009 | prostate cancer | Robert Dreicer MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00088413 Background | Jul 2004 → Apr 2018 | adenocarcinoma, breast cancer, colorectal cancer, ovarian carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00204607 Background | Jul 2004 → Jan 2007 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT00429416 Background | Mar 2004 → Dec 2008 | hematopoietic and lymphoid cell neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT00089219 Background | Jul 2003 → May 2006 | cutaneous melanoma, ocular melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 1/2 | NCT00048893 Background | Nov 2002 → Jun 2011 | breast cancer, metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00602706 Background | Jan 2000 → Jun 2003 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00004918 Background | Dec 1999 → Dec 2007 | acute myeloid leukemia, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome with excess blasts, refractory anemia with excess blasts in transformation | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2128 trials | ||||||
| Phase 2 | NCT05479045 Background | Sep 2026 → Nov 2027 expected | ovarian carcinoma, uterine adnexa cancer | Georgetown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06202066 Background | Jul 2026 → Oct 2027 expected | cancer, lung neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07169617 Background | Jul 2026 → Mar 2029 expected | lung carcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07537400 Background | May 2026 → Jun 2028 expected | neuroblastoma | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07078604 Background | Mar 2026 → Apr 2027 expected | female breast carcinoma, triple-negative breast carcinoma | University of Washington | Recruiting | No outcome recorded |
| Show all 128 trials opens the full record — a long page | ||||||
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00630565 Background | Jul 2006 → Jul 2022 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2/3 | NCT00090493 Background | Jun 2004 → Jul 2007 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT05266001 Comparator | Jun 2022 → Sep 2025 | multiple organ dysfunction syndrome | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04229979 Background | Feb 2021 → Dec 2025 overdue | acute myeloid leukemia | Sellas Life Sciences Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03126916 Background | May 2018 → Sep 2030 expected | neuroblastoma, nodular ganglioneuroblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01875653 Background | Oct 2014 → Jan 2016 | melanoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01480479 Background | Nov 2011 → Nov 2016 | giant cell glioblastoma, gliosarcoma, mixed astrocytoma-ependymoma-oligodendroglioma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01479244 Comparator | Nov 2011 → Sep 2016 | breast carcinoma by gene expression profile | Galena Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01265901 Background | Dec 2010 → Jul 2015 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01368276 Comparator | Oct 2010 → Sep 2014 | melanoma | BioVex Limited | Completed | No outcome recorded |
| Phase 3 | NCT00769704 Comparator | Apr 2009 → Feb 2013 | melanoma | BioVex Limited | Completed | No outcome recorded |
| Phase 3 | NCT00425360 Background | Sep 2006 → Mar 2013 | malignant pancreatic neoplasm | Royal Liverpool University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00293462 Comparator | Jun 2005 → Dec 2009 | mucositis, radiation-induced disorder, tongue cancer | Marilyn Dodd | Completed | No outcome recorded |
| Phase 3 | NCT00454168 Background | May 2005 → Apr 2009 | leukemia | The Vaccine Company | Unknown | No outcome recorded |
| Phase 3 | NCT00089115 Background | Jul 2004 → ? | lymphoma | Favrille | Terminated | No outcome recorded |
| Phase 3 | NCT00049517 Background | Dec 2002 → Mar 2009 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00046930 Background | Sep 2002 → Jun 2009 | myelodysplastic syndrome, myeloid leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003958 Background | Sep 2002 → Oct 2007 | adult malignant mesenchymoma, alveolar rhabdomyosarcoma, childhood botryoid rhabdomyosarcoma, childhood malignant mesenchymoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00017290 Background | Nov 2000 → ? | lymphoma | Genitope Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT00091676 Background | Jan 2000 → Dec 2012 | non-Hodgkin lymphoma | Biovest International | Unknown | No outcome recorded |
| Phase 3 | NCT00083551 Comparator | Aug 1998 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT00003972 Background | Jul 1998 → Mar 2003 | breast cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00003119 Background | Mar 1998 → Mar 2006 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002995 Background | Aug 1997 → Sep 2006 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00001561 Background | Nov 1996 → Sep 2005 | graft versus host disease, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00002766 Background | Mar 1996 → Sep 2011 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002599 Background | Sep 1994 → ? | plasma cell myeloma | Medical Research Council | Unknown | No outcome recorded |
| Phase 3 | NCT04446052 Comparator | May 1993 → Jul 2002 | acute myeloid leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002514 Background | May 1993 → Dec 2006 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003093 Background | Mar 1988 → Sep 2006 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00000658 Background | ? → Feb 1996 | HIV infectious disease, non-Hodgkin lymphoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00324831 Background | — | lymphoma | Favrille | Suspended | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06047535 Background | Oct 2023 → Jun 2027 expected | neuroblastoma | SciClone Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04326920 Comparator | Mar → Sep 2020 | COVID-19 | University Hospital, Ghent | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT02786719 Background | Jun 2016 → Feb 2019 | neuroblastoma | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT01828762 Background | Dec 2012 → Dec 2013 | hepatocellular carcinoma | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
| — | NCT01374711 Comparator | May → Nov 2011 | infectious disease with sepsis, multiple organ dysfunction syndrome | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00665002 Background | Jun 2008 → Jul 2013 | leukemia | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| — | NCT00912574 Comparator | Jun 2004 → Jul 2008 | melanoma | University of Virginia | Completed | No outcome recorded |
| — | NCT00228813 Background | Apr 2004 → Jan 2015 | hematopoietic and lymphoid system neoplasm | Emory University | Terminated | No outcome recorded |
| — | NCT00912418 Background | May 2000 → Sep 2002 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 601 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sargramostim | “Preliminary preclinical results demonstrated that GM-CSF (Granulocyte macrophage colony-stimulating factor, e.g. Leukine®/Sargramostim) rapidly reduced cerebral amyloid...” NCT01409915 ↗341“Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.” NCT01081808 ↗ “Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks” NCT01041417 ↗ “At the same time that patients get the SurVaxM/Montanide ISA 51 injection, they will also get a second subcutaneous injection of a medicine called sargramostim.” NCT04978727 ↗ “A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy” NCT04856176 ↗ “Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.” NCT00350597 ↗ “Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma” NCT00616564 ↗ “Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)” NCT05366062 ↗ “autologous dendritic cell mobilization with filgrastim (G-CSF) and/or sargramostim (GM-CSF) subcutaneously daily for 4 days” NCT00088985 ↗ “Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks.” NCT01511068 ↗ “All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination.” NCT01265433 ↗ “GM-CSF (granulocyte-macrophage colony stimulating factor, also called sargramostim, GM, or Leukine), a growth factor” NCT00208975 ↗ “Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine.” NCT00060528 ↗ “Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection” NCT00228813 ↗ “vaccination with TARP peptides in Montanide ISA 51 VG adjuvant plus Sargramostim will be studied” NCT00972309 ↗ “Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection” NCT02169609 ↗ “Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)” NCT04560166 ↗ “GM-CSF (Sargramostim) was co administered with each vaccine dose.” NCT00488592 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT01480479 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT00458601 ↗ “sargramostim (GM-CSF) SC on days 1-10” NCT00090870 ↗ “GM-CSF (also called sargramostim)” NCT02100930 ↗ “Leukine (Sargramostim, GM-CSF)” NCT01653665 ↗ “GM-CSF: Sargramostim (Leukine)” NCT01342224 ↗ “GM-CSF (Sargramostim)” NCT00433745 ↗ “sargramostim (GM-CSF)” NCT00091286 ↗ |
| Known as | Aerosol Sargramostim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05717140 ↗ |
| Known as | GM-CSF | “The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as...” NCT02933944 ↗335“OBJECTIVES: I. Determine the one year event-free survival in patients with chronic phase chronic myeloid leukemia receiving sargramostim (GM-CSF)-treated autologous bone marrow...” NCT00011934 ↗ “Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and...” NCT00005601 ↗ “The purpose of this study was to evaluate the feasibility of hypofractionated intensity-modulated radiation therapy (IMRT), temozolomide and granulocyte-macrophage...” PMID 40090128 ↗ Mar 2025 “Here, we tested our hypothesis that modulation of the innate immune system might similarly be used to treat AD in humans by investigating the ability of GM-CSF/sargramostim to...” PMID 33778150 ↗ Mar 2021 “Patients receive rituximab IV on days 4, 11, 18, and 25 and sargramostim (GM-CSF) subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, 40, 43,...” NCT00265915 ↗ “OBJECTIVES: I. Determine the therapeutic effects of aerosolized sargramostim (GM-CSF) in terms of progression free survival at 2 months and median survival rate in patients...” NCT00005610 ↗ “This treatment will combine peritumoral injection of IL-2, IFN-α and GM-CSF (6000 IU, 100.000 IU and 300 ng per tumor injected, respectively), as well as topical application of...” NCT01191034 ↗ “multiple peptide cocktail including LY6K and vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) together with IFA...” NCT00561275 ↗ “Personalized anti-tumor neoantigen injection (300 μg/peptide) plus GM-CSF (40 μg per injection site) will be administered via subcutaneous injection at multiple sites (around...” NCT07504484 ↗ “Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First...” NCT06047535 ↗ “Evaluate the effect of ketoconazole, hydrocortisone, and sargramostim (GM-CSF) on time to clinical progression in patients with prostate cancer that has progressed on primary...” NCT00309894 ↗ “Sargramostim (GM-CSF) and rituximab: Beginning approximately 7-10 weeks (49-70 days) after ASCT, patients receive GM-CSF SC 3 times a week for 8 weeks and rituximab IV once...” NCT00521014 ↗ “Patients also receive sargramostim (GM-CSF) subcutaneously (SC) alone on days 3-9 and GM-CSF and filgrastim (G-CSF) SC beginning on day 10 and continuing until leukapheresis is...” NCT00027937 ↗ “Patients receive high-dose sargramostim (GM-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover and then low-dose GM-CSF SC continuing until day 60.” NCT00002778 ↗ “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “GM-CSF, sargramostim 250 μg/m\^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.” NCT00157573 ↗ “Sargramostim (GM-CSF) is initiated subcutaneously 1 day later and is continued for 10 days to support stem cell collections, which begin 10-14 days after CTX induction.” NCT00003007 ↗ “We plan to determine whether using granulocyte-macrophage colony stimulating factor (GM-CSF) in this group would increase dose-intensity and ameliorate myelotoxicity.” NCT00001237 ↗ “In a separate trial, GMCSF was used in breast cancer patients treated with adriamycin based chemotherapy as the preferred growth factor in a neoadjuvant setting (16).” NCT00256243 ↗ “Patients are vaccinated with irradiated, autologous tumor cells plus sargramostim (GM-CSF) intradermally near draining lymph nodes in the groin or axillary regions.” NCT00003185 ↗ “E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections” NCT01479244 ↗ “STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)” NCT06934538 ↗ “Colorectal antigen 17-1A murine monoclonal antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor (Immunex), GM-CSF, NSC-613795.” NCT00002664 ↗ “AMENDED: To evaluate the effect of sargramostim ( GM-CSF ) on modulating the granulocytopenia associated with concomitant DHPG and AZT therapy ( Phase B )” NCT00000989 ↗ “granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).” NCT00030056 ↗ “Sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) is administered by subcutaneous injection on days 1-5 each week for 9 weeks.” NCT00003181 ↗ “Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.” NCT00350597 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14 and low-dose interleukin-2 (IL-2) SC on days 1-5, 8-12, 15-19, and 22-26.” NCT00085579 ↗ “Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma” NCT00616564 ↗ “Patients also receive sargramostim (GM-CSF) subcutaneously once daily beginning 2 days before every vaccination and continuing for 5 days.” NCT00027911 ↗ “adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination” NCT00000689 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily beginning between days -16 and -12 and continuing until day -1.” NCT00262808 ↗ “100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant.” NCT05479045 ↗ “At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe.” NCT02019524 ↗ “Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.” NCT01875653 ↗ “Patients receive sargramostim (GM-CSF) IV or subcutaneously daily beginning on day 7 and continuing until blood counts recover.” NCT00006747 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover.” NCT00602706 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).” NCT00003567 ↗ “autologous dendritic cell mobilization with filgrastim (G-CSF) and/or sargramostim (GM-CSF) subcutaneously daily for 4 days” NCT00088985 ↗ “Patients also receive an intratumoral injection of sargramostim (GM-CSF) to promote further ablation at the tumor site.” NCT00568763 ↗ “Sargramostim (GM-CSF) is administered subcutaneously (SC) beginning on day 1 and continuing until blood counts recover.” NCT00019097 ↗ “All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination.” NCT01265433 ↗ “AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.” NCT03743298 ↗ “daily neoadjuvant sargramostim (GM-CSF) in patients with localized prostate cancer undergoing radical prostatectomy.” NCT00305669 ↗ “the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function” NCT00000658 ↗ “Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).” NCT00850785 ↗ “Patients receive sargramostim (GM-CSF) SC daily beginning 1 day prior to the vaccination and continuing for 4 days.” NCT00019331 ↗ “Patients receive sargramostim (GM-CSF) SC once daily beginning on day 6 and continuing until blood counts recover.” NCT00242996 ↗ “granulocyte-monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL)-specific immune responses” PMID 21632504 ↗ May 2011 “Patients receive treatment as in arm I followed by sargramostim (GM-CSF) SQ for 5 days after each vaccination.” NCT00003274 ↗ “The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4).” NCT02705703 ↗ “Patients also receive sargramostim (GM-CSF) SC on days 1-4 of the same weeks as the Id-KLH conjugate vaccine.” NCT00621036 ↗ “using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity.” NCT00001239 ↗ “Patients receive paclitaxel IV over 3 hours on day 1 and sargramostim (GM-CSF) subcutaneously on days 4-17.” NCT00278122 ↗ “Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation.” NCT03392545 ↗ “Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.” NCT04062721 ↗ “GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses” NCT03645148 ↗ “Patients also receive sargramostim (GM-CSF) SC immediately after vaccination and once daily on days 1-4.” NCT00381875 ↗ “multi-epitope melanoma peptides (MP), tetanus toxoid helper peptide (TET), and sargramostim (GM-CSF)” NCT00118313 ↗ “Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.” NCT00047021 ↗ “sargramostim (GM-CSF) intratumorally continuously for 1 week and then subcutaneously for 2 weeks” NCT00091052 ↗ “Patients received GM-CSF at 250 mcg/m(2) subcutaneously for 14 days followed by 14 days of rest.” PMID 23210004 ↗ Jul 2011 “Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine” NCT02261714 ↗ “Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily” NCT00006483 ↗ “glioblastoma multiform multi-antigen vaccine IMA950 plus sargramostim (GM-CSF) in combination” NCT01222221 ↗ “Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover.” NCT00004162 ↗ “Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.” NCT00089063 ↗ “GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs.” NCT00090493 ↗ “CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)” NCT01094496 ↗ “Patients receive subcutaneous injections of sargramostim (GM-CSF) once a day for 5 days.” NCT00003490 ↗ “a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00458536 ↗ “Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.” NCT00454168 ↗ “Patients receive oral bexarotene and sargramostim (GM-CSF) subcutaneously on days 1-28.” NCT00425477 ↗ “subcutaneous sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF )” NCT00002263 ↗ “sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF )” NCT00002007 ↗ “Patients receive CAP 1-6D dissolved in sargramostim (GM-CSF) intradermally on day 1.” NCT00012246 ↗ “GM-CSF, or sargramostim, is a protein that acts as a white blood cell growth factor.” NCT05101356 ↗ “sargramostim (GM-CSF) SC beginning on day 3 and continuing until PBSC are harvested” NCT00017368 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously once daily on days -5 to 11.” NCT00089258 ↗ “Patients also receive sargramostim (GM-CSF) subcutaneously (SC) three times a week” NCT00008398 ↗ “granulocyte macrophage stimulating factor (GM-CSF), high-dose hepatitis B vaccine” NCT05451420 ↗ “MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously” NCT00374049 ↗ “then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6” NCT01878565 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1 and 2” NCT00466726 ↗ “patients are treated with sargramostim (GM-CSF) intravenously over 4 hours” NCT00003003 ↗ “Second, the patient will be vaccinated twice with those cells and GM-CSF.” NCT01081223 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously daily for 3 months” NCT00072579 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14.” NCT00908141 ↗ “granulocyte macrophage colony-stimulating factor (GM-CSF) (sargramostim)” NCT01989572 ↗ “Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF” NCT00302861 ↗ “sargramostim (GM-CSF; granulocyte-macrophage colony stimulating factor)” NCT00000681 ↗ “sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF)” NCT00002070 ↗ “Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)” NCT04560166 ↗ “Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week” NCT01543464 ↗ “Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT00969722 ↗ “granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide.” PMID 24520093 ↗ Feb 2014 “systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity” NCT00610389 ↗ “Patients receive sargramostim (GM-CSF) subcutaneously on days 5-60.” NCT00003961 ↗ “0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF” NCT00530140 ↗ “sargramostim (GM-CSF) SC into the same injection site once daily” NCT00103142 ↗ “sargramostim (GM-CSF) subcutaneously once daily on days -5 to 11” NCT00450307 ↗ “Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2” NCT03332667 ↗ “sargramostim (GM-CSF) SC twice in weeks 0, 4, 6, 8, 10, and 12” NCT00398138 ↗ “All patients receive sargramostim (GM-CSF) beginning on day 4.” NCT00003269 ↗ “Patients also receive sargramostim (GM-CSF) SC on days 1-4.” NCT00089115 ↗ “Patients also receive sargramostim (GM-CSF) SC on days 1-4.” NCT00104819 ↗ “sargramostim (GM-CSF) subcutaneously on days 1-7 and 15-21” NCT00006240 ↗ “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)” NCT01592045 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT01363206 ↗ “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)” NCT01555580 ↗ “Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT02709993 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT07537400 ↗ “During the TI, patients received sc GM-CSF (250 mcg TIW)” NCT00979706 ↗ “GM-CSF hematopoietic growth factor will start on Day 0.” NCT01049854 ↗ “Sargramostim (GM-CSF) SC is administered on days 1-4.” NCT00006478 ↗ “Patients receive oral sargramostim (GM-CSF) mouthwash” NCT00293462 ↗ “sargramostim (GM-CSF) subcutaneously (SC) on days 1-5” NCT00016042 ↗ “stereotactic radiosurgery and GM-CSF, Sapylin, MnCl2” NCT05131711 ↗ “sargramostim (GM-CSF) subcutaneously on days 5-21” NCT00002780 ↗ “4B5 in sargramostim (GM-CSF) subcutaneously (SQ)” NCT00004184 ↗ “sargramostim (GM-CSF) intradermally on days 1-10” NCT00003959 ↗ “sargramostim (GM-CSF) SC on days 1-4 of week 1” NCT00052351 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT00458601 ↗ “followed by sargramostim (GM-CSF) SQ on day 1” NCT00004198 ↗ “sargramostim (GM-CSF) SC daily on days 1-4” NCT00020254 ↗ “sargramostim (GM-CSF) subcutaneously (SC)” NCT00003125 ↗ “with sargramostim (GM-CSF) as an adjuvant” NCT00003002 ↗ “GM-CSF, 200ug/QD, subcutaneous injection” NCT06173219 ↗ “ESR1 peptides plus Montanide and GM-CSF” NCT04270149 ↗ “sargramostim (GM-CSF) IV over 2 hours” NCT00002560 ↗ “sargramostim (GM-CSF) subcutaneously” NCT00014560 ↗ “sargramostim (GM-CSF) subcutaneously” NCT00002552 ↗ “sargramostim (GM-CSF) SC on days 1-4” NCT00045227 ↗ “sargramostim (GM-CSF) SC on days 1-4” NCT00069940 ↗ “500 mcg/mL GP2 and 125 mcg/mL GM-CSF” NCT05232916 ↗ “the cytokine sargramostim (GM-CSF)” NCT00003315 ↗ “adjuvant sargramostim (GM-CSF) SC” NCT00017290 ↗ “sargramostim (GM-CSF) as adjuvant” NCT00003362 ↗ “GM-CSF (Sargramostim, Leukine®)” NCT00896519 ↗ “Leukine (Sargramostim, GM-CSF)” NCT01653665 ↗ “adjuvant sargramostim (GM-CSF)” NCT00005023 ↗ “Sargramostim (GM-CSF, Leukine)” NCT00088413 ↗ “cDNA for sargramostim (GM-CSF)” NCT00003897 ↗ “sargramostim (GM-CSF) SQ” NCT00019383 ↗ “sargramostim \[GM-CSF\]” NCT00899821 ↗ “GM-CSF (Sargramostim)” NCT00433745 ↗ “sargramostim (GM-CSF)” NCT00006113 ↗ “sargramostim (GM-CSF)” NCT00037037 ↗ “sargramostim (GM-CSF)” NCT00091273 ↗ “sargramostim (GM-CSF)” NCT00089206 ↗ “sargramostim (GM-CSF)” NCT00091286 ↗ “sargramostim (GM-CSF)” NCT00436930 ↗ “GM-CSF (sargramostim)” NCT00524277 ↗ “sargramostim (GM-CSF)” NCT00079157 ↗ “sargramostim (GM-CSF)” NCT00258336 ↗ “sargramostim (GM-CSF)” NCT00030342 ↗ “Sargramostim (GM-CSF)” NCT04703426 ↗ “Sargramostim (GM-CSF)” NCT00477815 ↗ “sargramostim (GM-CSF)” NCT00003408 ↗ “sargramostim (GM-CSF)” NCT00003184 ↗ “sargramostim (GM-CSF)” NCT00301951 ↗ “sargramostim (GM-CSF)” NCT00014092 ↗ “sargramostim (GM-CSF)” NCT00004024 ↗ “sargramostim (GM-CSF)” NCT00005630 ↗ “sargramostim (GM-CSF)” NCT00640861 ↗ “125 µg GM-CSF s.c.” NCT01022255 ↗ “GM-CSF: 40 mcg” NCT04810910 ↗ “Drug: GM CSF” NCT00274287 ↗ “Drug: GM-CSF” NCT01542684 ↗ “GM-CSF” NCT01536054 ↗ |
| Known as | GM-CSF (sargramostim) | “GM-CSF (sargramostim)” NCT00524277 ↗ |
| Known as | GM-CSF = Leukine | “GM-CSF = Leukine” NCT01627678 ↗ |
| Known as | GM-CSF: molgramostim | “GM-CSF: molgramostim” NCT00880243 ↗ |
| Known as | GMCSF (granulocyte macrophage colony stimulating factor) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006184 ↗ |
| Known as | granulocyte and macrophage colony-stimulating factor | “topical granulocyte and macrophage colony-stimulating factor (GM-CSF) and miltefosine (G + M) versus placebo and miltefosine (P + M)” PMID 33253864 ↗ Nov 2020 |
| Known as | Granulocyte Macrophage Colony Stimulation Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04408092 ↗ |
| Known as | granulocyte macrophage colony- stimulating factor (GM-CSF) | “granulocyte macrophage colony- stimulating factor (GM-CSF)” NCT00488592 ↗3“Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT07537400 ↗ |
| Known as | granulocyte-macrophage colony-stimulating factor | “The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as...” NCT02933944 ↗74“Through compassionate use, 4 patients with progression of disease or refractory disease after HITS therapy, have been further treated with two cycles of a combination of...” NCT06438614 ↗ “The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin,...” NCT00455897 ↗ “We aimed to investigate the safety of intraperitoneal administration of the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage...” PMID 31040341 ↗ Apr 2019 “Although IFN-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) restore immune competence of ex vivo stimulated leukocytes of patients with sepsis, effects on...” PMID 22822024 ↗ Jul 2012 “Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly...” NCT00272493 ↗ “Their phase 1-2 trials revealed that the E75 + granulocyte-macrophage colony-stimulating factor (GM-CSF) vaccine is safe and effective in stimulating clonal expansion of...” PMID 20845479 ↗ Sep 2010 “The purpose of this study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for...” NCT01757626 ↗ “PRaG therapy, which combines PD-1/PD-L1 inhibitors, radiotherapy, and granulocyte-macrophage colony-stimulating factor (GM-CSF), aims to treat patients with advanced, refractory tumors.” PMID 41308040 ↗ Nov 2025 “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks.” NCT00769704 ↗ “three (3) days of subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to increase bone marrow production of monocytes and dendritic cell (DC) precursors” NCT02705703 ↗ “Treatment of autoimmune pulmonary alveolar proteinosis (aPAP) by inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) is considered safe and effective.” PMID 32615994 ↗ Jul 2020 “Administration of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to patients with pancreatic adenocarcinoma will result in enhance recruitment of DCs” NCT00600002 ↗ “Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy.” NCT06651853 ↗ “Participants will receive SL-701 with the vaccine adjuvants granulocyte macrophage-colony stimulating factor (GM-CSF) injection and imiquimod topical cream.” NCT02078648 ↗ “Colorectal antigen 17-1A murine monoclonal antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor (Immunex), GM-CSF, NSC-613795.” NCT00002664 ↗ “granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).” NCT00030056 ↗ “Sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) is administered by subcutaneous injection on days 1-5 each week for 9 weeks.” NCT00003181 ↗ “the granulocyte macrophage-colony stimulating factor (GM-CSF) for the Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS (GRACE)-2 trial” PMID 37498156 ↗ Jul 2023 “The vaccine/adjuvant combination will be evaluated with or without coadministration of granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00076037 ↗ “100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant.” NCT05479045 ↗ “Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine promoting leukocyte proliferation and trophoblast growth.” PMID 40965804 ↗ Sep 2025 “Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine ®) will be used as adjuvant for 11 of the 13 doses of UV1.” NCT01789099 ↗ “Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion” NCT00834665 ↗ “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) during induction and consolidation courses versus no priming.” NCT00880243 ↗ “AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.” NCT03743298 ↗ “the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function” NCT00000658 ↗ “granulocyte macrophage-colony stimulating factor (GM-CSF) or placebo conducted at three academic medical centers.” PMID 28358594 ↗ Jun 2017 “using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity.” NCT00001239 ↗ “granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin-2 (IL-2)” NCT01176552 ↗ “hepatitis B immune globin (HBIG)+granulocyte-macrophage colony-stimulating factor (GM-CSF)+HBV vaccine” NCT01878565 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody” NCT03363373 ↗ “Naxitamab will be combined with granulocyte-macrophage colony stimulating factor (GM-CSF).” NCT04501757 ↗ “GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor (Hoechst/Immunex), NSC-613795” NCT00001561 ↗ “Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab” NCT06345599 ↗ “granulocyte-macrophage colony-stimulating factor (GM-CSF) (0.03 mg/injection)” PMID 39998682 ↗ Feb 2025 “sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF )” NCT00002006 ↗ “sargramostim (GM-CSF; granulocyte-macrophage colony stimulating factor)” NCT00000681 ↗ “sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF)” NCT00002070 ↗ “subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF)” NCT02774421 ↗ “granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide.” PMID 24520093 ↗ Feb 2014 “adjuvant GM-CSF (Granulocyte Macrophage Colony-stimulating Factor)” NCT03559413 ↗ “Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)” NCT00912418 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT02502786 ↗ “GM-CSF (granulocyte-macrophage colony-stimulating factor)” NCT02100930 ↗ “Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” NCT02709993 ↗ “granulocyte macrophage colony-stimulating factor (GM-CSF)” NCT00948480 ↗ “Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT06047535 ↗ “Granulocyte macrophage colony stimulating factor (GM-CSF)” NCT02261714 ↗ “GM-CSF (granulocyte-macrophage colony-stimulating factor)” NCT06989333 ↗ “granulocyte-macrophage colony stimulating factor (GM-CSF)” PMID 34526044 ↗ Sep 2021 “granulocyte-macrophage colony stimulating factor (GM-CSF)” NCT01183897 ↗ “granulocyte-macrophage colony stimulating factor” NCT04100655 ↗ “Granulocyte Macrophage Colony Stimulating Factor” NCT01232504 ↗ |
| Known as | Granulocyte-macrophage stimulating factor | “Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity” PMID 22270330 ↗ Jan 20121“granulocyte macrophage stimulating factor (GM-CSF)” NCT05451420 ↗ |
| Known as | Granulocyte-Macrophage Stimulating-Colony Factor | “The purpose of this study was to investigate the potential effects of Granulocyte-Macrophage Stimulating-Colony Factor (GM-CSF) supplementation in embryo culture for patients...” NCT02250768 ↗ |
| Known as | granulocyte-monocyte colony-stimulating factor | “granulocyte-monocyte colony-stimulating factor (GM-CSF)” PMID 21632504 ↗ May 2011 |
| Known as | GZ402664 | “Sargramostim GZ402664” NCT02667496 ↗ |
| Known as | IMA910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785122 ↗ |
| Known as | Leucomax | “GM-CSF (Leucomax, recombinant human GM-CSF from Escherichia Coli, Schering Plough, Kenilworth,N.J., USA) is given at a dose of 5µg/kg per day, intravenously beginning at day 1...” NCT00880243 ↗ |
| Known as | Leukine | “Interferon gamma 1b (Actimmune) and GM-CSF (Leukine) are two cytokine therapies that have been approved in the treatment of chronic granulomatous disease and...” NCT00111397 ↗27“E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections” NCT01479244 ↗ “Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease” NCT00206700 ↗ “Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.” NCT00350597 ↗ “Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)” NCT05366062 ↗ “Immunologic Effects of GM-CSF (Sargramostim, Leukine®) in Patients With Biochemically-relapsed Prostate Cancer” NCT00908141 ↗ “Patients will receive hematopoietic growth factor support with either Leukine (Arm A), or Neupogen (Arm B).” NCT00237575 ↗ “Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection” NCT00228813 ↗ “escalating dose of GM-CSF (Leukine) up to 250 mcg.” NCT01527422 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT01480479 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT00458601 ↗ “Sargramostim: Leukine (Genzyme USA)” NCT02361528 ↗ “GM-CSF (Sargramostim, Leukine®)” NCT00896519 ↗ “Sargramostim (GM-CSF, Leukine)” NCT00088413 ↗ “Sargramostim (GM-CSF, Leukine)” NCT00450463 ↗ “Leukine (Sargramostim, GM-CSF)” NCT01653665 ↗ “Drug: Sargramostim (Leukine)” NCT00329537 ↗ “Sargramostim (Leukine)” NCT00206713 ↗ “Sargramostim (Leukine)” NCT00206674 ↗ “Sargramostim (Leukine)” NCT00206661 ↗ “Sargramostim (Leukine)” NCT00206596 ↗ “Sargramostim (Leukine)” NCT00295165 ↗ “Leukine” NCT00571662 ↗ |
| Known as | Leukine (Sargramostim) | “Leukine (Sargramostim)” NCT01527422 ↗ |
| Known as | Leukomax | “Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)” NCT05366062 ↗ |
| Known as | Molgramostim | “GM-CSF (Molgramostim, TOPLEUCON®; Xiamen Amoytop Biotech Co., Ltd., China)” NCT01232504 ↗ |
| Known as | NSC-613795 | “Colorectal antigen 17-1A murine monoclonal antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor (Immunex), GM-CSF, NSC-613795.” NCT00002664 ↗1“GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor (Hoechst/Immunex), NSC-613795” NCT00001561 ↗ |
| Known as | Recombinant GM-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083551 ↗ |
| Known as | recombinant granulocyte-macrophage colony-stimulating factor | “adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination” NCT00000689 ↗1“sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF )” NCT00002007 ↗ |
| Known as | Recombinant human GM-CSF | “Recombinant human GM-CSF” NCT02411786 ↗ |
| Known as | Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor | “GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected.” NCT00952237 ↗ |
| Known as | rGM-CSF | “Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of...” NCT04408092 ↗ |
| Known as | rhGM-CSF | “We aimed to investigate the safety of intraperitoneal administration of the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage...” PMID 31040341 ↗ Apr 20191“Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF)” NCT01232504 ↗ |
| Known as | rhu GM-CSF | “GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system.” NCT03282188 ↗7“Priming with Granulocyte-Macrophage Colony Stimulating Factor (rhu-GM-CSF)” NCT04446052 ↗ “Leukine® (rhu-GM-CSF)” NCT01704781 ↗ |
| Known as | Sagramostim | “Sagramostim” NCT05421897 ↗ |
| Known as | sangramostim | “PURPOSE: To determine the biologic effect of granulocyte-macrophage colony-stimulating factor (sangramostim, GM-CSF; Immunex Corporation, Seattle, WA) as measured by...” PMID 12506177 ↗ Jan 2003 |
| Known as | Sargramostim (GM-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00665002 ↗ |
| Known as | Topleucon | “Topleucon®” NCT01232504 ↗ |
| Action | Activate | “Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system” NCT00006385 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human GM-CSF is a human protein” NCT00000694 ↗ |
| Route | Subcutaneous | “IFN-A2b and GM-CSF are given in two separate injections under the skin (subcutaneous injection) once a day” NCT00000694 ↗ |